Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesCardiologySummaCare LAAC Coverage Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentSummaCarePolicy N/A

    Percutaneous Left Atrial Appendage Closure (LAAC) Policy

    Customize your policy alerts

    Sign up for all summacare policy alerts

    Know when summacare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and medical-necessity requirements for percutaneous left atrial appendage closure (LAAC) in commercial and Medicare members with nonvalvular atrial fibrillation. Commercial coverage follows SummaCare criteria, while Medicare coverage follows CMS National Coverage Determination requirements; self-funded commercial groups must consult their plan documents.

    Policy Summary
    PayerSummaCare
    PolicyPercutaneous Left Atrial Appendage Closure (LAAC) Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date10/8/26
    Next Review DateN/A
    Key ActionBefore LAAC, obtain and document formal shared decision-making with an independent non-interventional physician using an evidence-based oral-anticoagulation decision tool.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Member populations addressed
    ≥25Required transeptal procedures
    ≥12Required LAAC procedures over 2 years
    ≥4 years

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Registry tracking period
    3CPT codes listed
    All otherOther indications considered experimental

    Medical Necessity and Coverage Requirements

    Commercial member medical-necessity criteria

    Commercial members: covered when ALL of the following are met.

    Commercial LAAC coverage

    • Stroke-risk threshold: CHADS2 score > 2 or CHA2DS2-VASc score > 3.CHADS2 > 2 OR CHA2DS2-VASc > 3
    • Shared decision-making: A formal shared decision-making interaction occurs with an independent non-interventional physician using an evidence-based oral-anticoagulation decision tool, and the interaction is documented in the medical record.
    • Anticoagulation and care setting: The patient is suitable for short-term warfarin but unable to take long-term oral anticoagulation after shared decision-making; LAAC is used as second-line therapy; the patient is managed preoperatively and postoperatively by a cohesive multidisciplinary team; and the procedure is furnished in a hospital with an established structural heart disease and/or electrophysiology program.
    • Operator qualifications: The operator is an interventional cardiologist, electrophysiologist, or cardiovascular surgeon who completed manufacturer training, has performed more than 25 interventional cardiac procedures involving transeptal puncture through an intact septum, and continues to perform more than 25 such procedures over a 2-year period, including at least 12 LAAC procedures.>25 prior; >25 over 2 years including ≥12 LAAC
    • Registry participation: No additional registry participation condition is specified for commercial members.

    Medicare member medical-necessity criteria

    Medicare members: covered under CMS Coverage with Evidence Development when ALL of the following are met.

    Medicare LAAC coverage

    • Stroke-risk threshold: CHADS2 score ≥ 2 or CHA2DS2-VASc score ≥ 3.CHADS2 ≥ 2 OR CHA2DS2-VASc ≥ 3
    • Shared decision-making: A formal shared decision-making interaction occurs with an independent non-interventional physician using an evidence-based oral-anticoagulation decision tool, and the interaction is documented in the medical record.
    • Anticoagulation and care setting: The patient is suitable for short-term warfarin but unable to take long-term oral anticoagulation after shared decision-making; LAAC is used as second-line therapy; the patient is managed preoperatively and postoperatively by a cohesive multidisciplinary team; and the procedure is furnished in a hospital with an established structural heart disease and/or electrophysiology program.

    Cardiac devices for occlusion of the left atrial appendage are considered experimental and investigational for all indications outside the policy’s covered criteria.

    Codes, Thresholds, and Operational Requirements

    CPT CodesCPT
    33267Exclusion of left atrial appendage, open, any method
    33268Exclusion of left atrial appendage, open, performed at the time of other sternotomy or thoracotomy procedure(s), any method
    33269Exclusion of left atrial appendage, thoracoscopic, any method
    Commercial CHADS2 score
    Member populationCommercial members
    CHADS2 requirementGreater than 2
    Coverage contextRequired for FDA-approved LAAC in nonvalvular atrial fibrillation
    Commercial CHA2DS2-VASc score
    Member populationCommercial members
    CHA2DS2-VASc requirementGreater than 3
    Coverage contextRequired for FDA-approved LAAC in nonvalvular atrial fibrillation

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Meet the Stroke-Risk Threshold

    Confirm that the patient meets the applicable stroke-risk threshold before requesting authorization. SummaCare’s commercial criteria require a CHADS2 score > 2 or CHA2DS2-VASc score > 3; CMS nationally covered indications use CHADS2 ≥ 2 or CHA2DS2-VASc ≥ 3.

    • Document the component risk factors and calculated score in the medical record.
    • CHADS2 factors: congestive heart failure, hypertension, age > 75, diabetes, and prior stroke/TIA/thromboembolism.
    • CHA2DS2-VASc factors: congestive heart failure, hypertension, age, diabetes, prior stroke/TIA/thromboembolism, vascular disease, and sex category.
    Documentation Required

    Document Shared Decision-Making

    Complete and document a formal shared decision-making interaction with an independent non-interventional physician before LAAC. The consultation must use an evidence-based decision tool addressing oral anticoagulation in patients with NVAF.

    Clinical Background

    The left atrial appendage (LAA) is a tubular structure that opens into the left atrium. It may be a site where thrombi, or blood clots, form.

    In patients with atrial fibrillation, thrombi originating in the LAA may embolize and cause ischemic stroke. Oral anticoagulation is an established preventive treatment, while percutaneous left atrial appendage closure is a nonpharmacologic alternative for selected patients with nonvalvular atrial fibrillation who cannot take long-term oral anticoagulation.

    Key Terms and Risk Scores

    Left atrial appendage (LAA)
    StructureA tubular structure that opens into the left atrium
    Clinical significanceA potential source of blood clots
    Stroke relationshipClots may migrate from the LAA and cause strokes
    Nonvalvular atrial fibrillation (NV AF)
    DefinitionAtrial fibrillation without valvular atrial disease
    Covered contextThe policy applies percutaneous LAAC criteria to patients with NV AF
    Device requirement
    Policy Summary
    PayerSummaCare
    PolicyPercutaneous Left Atrial Appendage Closure (LAAC) Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date10/8/26
    Next Review DateN/A
    Key ActionBefore LAAC, obtain and document formal shared decision-making with an independent non-interventional physician using an evidence-based oral-anticoagulation decision tool.
    SourceLink
    On This Page
    Medical Necessity and Coverage RequirementsCodes, Thresholds, and Operational RequirementsAuthorization, Documentation, and Denial RisksClinical BackgroundKey Terms and Risk Scores
  1. Operator qualifications: The operator is an interventional cardiologist, electrophysiologist, or cardiovascular surgeon who completed manufacturer training, has performed at least 25 interventional cardiac procedures involving transeptal puncture through an intact septum, and continues to perform at least 25 such procedures over a 2-year period, including at least 12 LAAC procedures.≥25 prior; ≥25 over 2 years including ≥12 LAAC
  2. Registry participation: The patient, multidisciplinary team, and hospital participate in a prospective, national, audited registry that consecutively enrolls LAAC patients and tracks specified annual outcomes for at least 4 years from the time of LAAC.At least 4 years

    Tracked outcomes include operator-specific complications; device-specific complications, including device thrombosis; adjudicated stroke by type; transient ischemic attack; systemic embolism; death; and major bleeding by site and severity.

  3. Medicare CHADS2 score
    Member populationMedicare members
    CHADS2 requirementAt least 2
    Coverage contextCovered through CMS Coverage with Evidence Development for nonvalvular atrial fibrillation
    Medicare CHA2DS2-VASc score
    Member populationMedicare members
    CHA2DS2-VASc requirementAt least 3
    Coverage contextCovered through CMS Coverage with Evidence Development for nonvalvular atrial fibrillation
    Operator transeptal procedure experience
    Prior experienceAt least 25 interventional cardiac procedures involving transeptal puncture through an intact septum
    Ongoing experienceContinues to perform at least 25 such procedures over a 2-year period
    LAAC experienceAt least 12 of the procedures over that 2-year period must be LAAC procedures
    Registry outcome tracking
    Tracking periodAt least 4 years from the time of LAAC
    Registry requirementProspective, national, audited registry that consecutively enrolls LAAC patients
    Annual outcomesTracks complications, device thrombosis, stroke, TIA, systemic embolism, death, and major bleeding
    • Record the consultation and decision in the medical record.
    • Document the discussion of oral-anticoagulation benefits, risks, and alternatives.
    Prior Authorization

    Establish Second-Line Anticoagulation Status

    Establish that the patient is suitable for short-term warfarin but is unable to take long-term oral anticoagulation after shared decision-making. LAAC is covered only as second-line therapy to oral anticoagulants.

    • Document short-term warfarin suitability.
    • Document the clinical basis for inability to take long-term oral anticoagulation.
    • Document that oral anticoagulation was considered before LAAC.
    Prior Authorization

    Use a Qualified Facility and Multidisciplinary Team

    Verify that the patient is managed preoperatively and postoperatively by a cohesive, multidisciplinary team (MDT), and that the procedure is furnished in a hospital with an established structural heart disease (SHD) and/or electrophysiology (EP) program.

    • Identify the participating medical professionals and their roles.
    • Confirm the hospital’s established SHD and/or EP program.
    • Document both preoperative and postoperative MDT involvement.
    Documentation Required

    Verify Operator Qualifications

    Confirm that the LAAC operator is an interventional cardiologist, electrophysiologist, or cardiovascular surgeon who satisfies all training and procedural-experience requirements.

    • Manufacturer training on safe and effective device use must be completed before performing LAAC.
    • The operator must have performed > 25 interventional cardiac procedures involving transeptal puncture through an intact septum under SummaCare’s commercial criteria; CMS uses ≥ 25.
    • The operator must continue to perform > 25 such procedures over a two-year period, including at least 12 LAAC procedures.
    Documentation Required

    Confirm Registry Participation and Outcome Tracking

    Confirm that the patient, MDT, and hospital participate in a prospective, national, audited registry. The registry must consecutively enroll LAAC patients and track required outcomes annually for at least four years from LAAC.

    • Document patient enrollment and participation by the MDT and hospital.
    • Track operator-specific complications and device-specific complications, including device thrombosis.
    • Track adjudicated stroke by type, TIA, systemic embolism, and death.
    • Track major bleeding by site and severity.
    • Maintain annual outcome tracking for at least four years after LAAC.
    Prior Authorization

    Oral Anticoagulation Must Be Considered First

    LAAC must be considered only after oral anticoagulation has been evaluated. SummaCare covers LAAC as a second-line therapy to oral anticoagulants, not as an initial alternative without the required assessment.

    • Document consideration of oral anticoagulation before the procedure.
    • Document the patient’s suitability for short-term warfarin and inability to take long-term oral anticoagulation.
    Prior Authorization

    Document Patient Eligibility and Device Indication

    Document nonvalvular atrial fibrillation (NVAF), use of a device with FDA Premarket Approval (PMA) for the device’s FDA-approved indication, and the applicable stroke-risk score.

    • Confirm the arrhythmia is nonvalvular atrial fibrillation.
    • Confirm the device has FDA PMA for the proposed indication.
    • Document the applicable CHADS2 or CHA2DS2-VASc score and threshold.
    Documentation Required

    Complete Shared Decision-Making and Anticoagulation Assessment

    The record must contain the independent non-interventional physician consultation, the evidence-based oral-anticoagulation decision tool, the shared decision-making outcome, and the assessment supporting short-term warfarin suitability but inability to take long-term oral anticoagulation.

    • Complete the consultation before LAAC.
    • Document the oral-anticoagulation discussion and conclusion.
    • Document why LAAC is being used as second-line therapy.
    Documentation Required

    Document Team, Facility, and Operator Qualifications

    Document the cohesive preoperative and postoperative MDT, the hospital’s established SHD and/or EP program, and the operator’s specialty, manufacturer training, and procedural experience.

    • Identify the MDT and document its preoperative and postoperative care involvement.
    • Identify the qualified hospital program.
    • Document operator specialty and manufacturer training.
    • Document the required transeptal-procedure and LAAC experience.
    Documentation Required

    Document Registry Participation and Outcome Tracking

    Document enrollment of the patient, MDT, and hospital in the required prospective, national, audited registry and maintain annual outcome tracking for at least four years after LAAC.

    • The registry must consecutively enroll LAAC patients.
    • Track operator-specific and device-specific complications, including device thrombosis.
    • Track stroke by type, TIA, systemic embolism, death, and major bleeding by site and severity.
    • Retain evidence of annual tracking for at least four years.
    Denial Risk

    Patient or Device Does Not Meet the Covered Indication

    Authorization or coverage is at risk when the patient or device does not satisfy the covered indication. SummaCare considers cardiac devices for left atrial appendage occlusion experimental and investigational for all other indications.

    • Patient must have nonvalvular atrial fibrillation.
    • Device must have FDA PMA for the proposed FDA-approved indication.
    • The applicable covered stroke-risk threshold must be met.
    • An indication outside the covered criteria may be denied as experimental or investigational.
    Denial Risk

    Anticoagulation Evaluation or Documentation Is Incomplete

    Coverage may be denied when shared decision-making or anticoagulation documentation is missing or incomplete.

    • Missing independent non-interventional physician consultation or evidence-based decision tool.
    • Shared decision-making is not documented in the medical record.
    • No documentation of short-term warfarin suitability.
    • No documentation that the patient cannot take long-term oral anticoagulation.
    • No documentation that oral anticoagulation was considered first.
    Denial Risk

    Facility, Team, or Operator Requirements Are Not Met

    Coverage may be denied when the hospital, MDT, or operator does not meet the required qualifications.

    • Hospital lacks an established SHD and/or EP program.
    • Cohesive preoperative and postoperative MDT care is not documented.
    • Operator lacks required manufacturer training or specialty qualification.
    • Operator does not meet the required transeptal-procedure or LAAC experience thresholds.
    Denial Risk

    Registry Participation or Covered Indication Is Absent

    Coverage may be denied when required registry participation is absent or when the procedure is performed for an indication outside the covered criteria.

    • Patient, MDT, or hospital is not enrolled in the prospective, national, audited registry.
    • Registry does not consecutively enroll LAAC patients or track required annual outcomes for at least four years.
    • Patient lacks NVAF, the device lacks FDA PMA for the proposed indication, or the applicable stroke-risk threshold is not met.
    • An indication outside SummaCare’s covered criteria may be considered experimental and investigational.
    The device must have FDA Premarket Approval for its FDA-approved indication
    CHADS2
    PurposeStroke-risk score
    ComponentsCongestive heart failure, hypertension, age 75 years or older, diabetes mellitus, and prior stroke, TIA, or thromboembolism
    Prior stroke-related eventsStroke, TIA, or thromboembolism contributes 2 points
    CHA2DS2-VASc
    PurposeExpanded stroke-risk score
    ComponentsCongestive heart failure, hypertension, age, diabetes, prior stroke/TIA/thromboembolism, vascular disease, and sex category
    Age weightingAge 75 years or older contributes 2 points; age 65 to 74 years contributes 1 point
    Prior stroke-related eventsStroke, TIA, or thromboembolism contributes 2 points
    Shared decision-making
    ConsultationFormal shared decision-making interaction with an independent non-interventional physician
    Decision toolUse an evidence-based decision tool on oral anticoagulation in patients with nonvalvular atrial fibrillation
    Timing and documentationComplete before LAAC and document the interaction in the medical record